Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26810500 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA2AADORA3P2RY12 | |
| SCHEMBL29325179 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA2AADORA3P2RY12 | |
| SCHEMBL29325188 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA2AADORA3P2RY12 | |
| SCHEMBL29323356 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA2AADORA3P2RY12 | |
| SCHEMBL14367294 | 0.94 | ADORA2A (0.52) | CYP3A4CYP2C9ADORA2AADORA3P2RY12 | |
| SCHEMBL16080921 | 0.94 | CYP3A4 (0.56) | CYP3A4CYP2C9ADORA2AP2RY12 | |
| SCHEMBL16080918 | 0.94 | CYP3A4 (0.56) | CYP3A4CYP2C9ADORA2AP2RY12 | |
| SCHEMBL16080959 | 0.94 | CYP3A4 (0.56) | CYP3A4CYP2C9ADORA2AP2RY12 | |
| SCHEMBL15588446 | 0.93 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA2AP2RY12 | |
| SCHEMBL16480936 | 0.93 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | NSUN2, ACE2, PNP | CYP3A4 344/4885CYP2C9 1644/4885ADORA2A 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.